PDCD1 and pancreatic neoplasm: Currently, several clinical studies (NCT02648282, NCT03336216, NCT03190265, NCT02451982, NCT02558894, NCT02309177, NCT02303990, NCT02546531, NCT01714739, NCT03404960, NCT03006302) are ongoing based on combination of a vaccine (GVAX or CRS-207) and anti-PD-1 therapy in pancreatic cancer patients.